Grifols (NASDAQ:GRFS) Earns Overweight Rating from Analysts at Morgan Stanley

Morgan Stanley started coverage on shares of Grifols (NASDAQ:GRFS) in a report published on Wednesday morning. The brokerage issued an overweight rating on the biotechnology company’s stock.

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Down 2.5 %

GRFS opened at $7.01 on Wednesday. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company’s 50-day moving average price is $7.37 and its 200 day moving average price is $8.09. Grifols has a fifty-two week low of $5.30 and a fifty-two week high of $9.96.

Institutional Trading of Grifols

Several hedge funds have recently bought and sold shares of the company. Orion Portfolio Solutions LLC acquired a new stake in shares of Grifols in the fourth quarter valued at approximately $119,000. Norges Bank acquired a new stake in Grifols in the 4th quarter valued at approximately $14,434,000. Anthracite Investment Company Inc. increased its position in Grifols by 7.4% in the 4th quarter. Anthracite Investment Company Inc. now owns 659,964 shares of the biotechnology company’s stock valued at $4,910,000 after acquiring an additional 45,410 shares during the period. Financial Engines Advisors L.L.C. bought a new stake in Grifols during the 4th quarter valued at $358,000. Finally, LPL Financial LLC boosted its position in Grifols by 25.0% during the 4th quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company’s stock worth $561,000 after acquiring an additional 15,067 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.